COVID-19 Update 77 with Roger Seheult, MD. All coronavirus updates available free at our website https://www.medcram.com/courses/coronavirus-outbreak-symptoms-treatment
(This video was recorded on May 31, 2020)
——————————————-
Links referenced in this video:
Johns Hopkins Tracker – https://coronavirus.jhu.edu/map.html
Worldometer https://www.worldometers.info/coronavirus/
Medical News Today – https://www.medicalnewstoday.com/articles/science-vs-covid-19-vaccine-trial-wins-and-other-hopeful-findings#Convalescent-plasma-therapy-safe
The experimental drug remdesivir has been approved to treat hospitalized patients with severe Covid-19, the US Food and Drug Administration said.
The FDA issued an emergency-use authorization, saying the benefits of the drug outweigh its risks in patients. An emergency-use authorization is a lower regulatory bar than full FDA approval. CNN’s Sara Sidner reports.
#Coronavirus #CNN #News
A drug that may shorten the recovery time of hospitalized coronavirus patients is being hailed as a potential breakthrough in the fight against the pandemic. Dr. Anthony Fauci lauded the drug remdesivir’s “positive effect in diminishing the time to recovery” for patients in a clinical trial. While the drug is not yet approved, President Trump urged the FDA to get through the process as soon as possible. Ben Tracy reports from the White House, where daily task force briefings have been replaced with economy-focused events.
The White House says they are cautiously optimistic after recent trials of Ebola drug Remdesivir on COVID-19 patients around the world, it lowered the death rate and improved recovery speed. Subscribe: https://bit.ly/2noaGhv Get more breaking news at: https://bit.ly/2nobVgF
Join Nine News for the latest in news and events that affect you in your local city, as well as news from across Australia and the world.
Follow Nine News on Facebook: https://www.facebook.com/9News/
Follow Nine News on Twitter: https://twitter.com/9NewsAUS
Follow Nine News on Instagram: https://www.instagram.com/9news/
